| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.5 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |